Your browser doesn't support javascript.
loading
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio, Cecilia; Bouabdallah, Reda; Ysebaert, Loïc; Sancho, Juan-Manuel; Salles, Gilles; Cordoba, Raul; Pinto, Antonio; Gharibo, Mecide; Rasco, Drew; Panizo, Carlos; Lopez-Martin, Jose A; Santoro, Armando; Salar, Antonio; Damian, Silvia; Martin, Alejandro; Verhoef, Gregor; Van den Neste, Eric; Wang, Maria; Couto, Suzana; Carrancio, Soraya; Weng, Andrew; Wang, Xuehai; Schmitz, Frank; Wei, Xin; Hege, Kristen; Trotter, Matthew W B; Risueño, Alberto; Buchholz, Tonia J; Hagner, Patrick R; Gandhi, Anita K; Pourdehnad, Michael; Ribrag, Vincent.
Afiliação
  • Carpio C; Department of Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Universitat Autònoma of Barcelona, Barcelona, Spain.
  • Bouabdallah R; Institut Paoli-Calmettes, Marseille, France.
  • Ysebaert L; Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
  • Sancho JM; Catalan Institute of Oncology (ICO)-Josep Carreras Leukaemia Research Institute (IJC)-Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Salles G; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
  • Cordoba R; Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Pinto A; Istituto Nazionale Tumori, Fondazione G. Pascale, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Napoli, Italy.
  • Gharibo M; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
  • Rasco D; South Texas Accelerated Research Therapeutics LLC, San Antonio, TX.
  • Panizo C; Clinica Universidad de Navarra, Pamplona, Spain.
  • Lopez-Martin JA; 12 de Octubre University Hospital & Research Institute, Grupo Español de Terapias Inmuno-Biológicas en Cáncer (GÉTICA), Madrid, Spain.
  • Santoro A; Humanitas Research Hospital and Cancer Center, Milan, Rozzano, Italy.
  • Salar A; Hospital del Mar, Barcelona, Spain.
  • Damian S; Fondazione IRCCS, Milan, Italy.
  • Martin A; Hospital Universitario de Salamanca and Instituto de Investigación Biomedica de Salamanca (IBSAL), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain.
  • Verhoef G; UZ Gasthuisberg Leuven, Leuven, Belgium.
  • Van den Neste E; Cliniques Universitaires Saint-Luc, Université de Louvain, Brussels, Belgium.
  • Wang M; Bristol-Myers Squibb, San Diego, CA.
  • Couto S; Genmab Pharmaceuticals, Princeton, NJ.
  • Carrancio S; Bristol-Myers Squibb, San Diego, CA.
  • Weng A; Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Wang X; Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Schmitz F; Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Wei X; Bristol-Myers Squibb, Berkeley Heights, NJ.
  • Hege K; Bristol-Myers Squibb, San Francisco, CA.
  • Trotter MWB; Celgene Institute for Translational Research Europe, A Bristol-Myers Squibb Company, Seville, Spain.
  • Risueño A; Celgene Institute for Translational Research Europe, A Bristol-Myers Squibb Company, Seville, Spain.
  • Buchholz TJ; Bristol-Myers Squibb, San Francisco, CA.
  • Hagner PR; Bristol-Myers Squibb, Summit, NJ; and.
  • Gandhi AK; Bristol-Myers Squibb, Summit, NJ; and.
  • Pourdehnad M; Bristol-Myers Squibb, San Francisco, CA.
  • Ribrag V; Institut Gustave Roussy, Villejuif, France.
Blood ; 135(13): 996-1007, 2020 03 26.
Article em En | MEDLINE | ID: mdl-31977002
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidonas / Linfoma Difuso de Grandes Células B / Quinazolinonas / Antineoplásicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidonas / Linfoma Difuso de Grandes Células B / Quinazolinonas / Antineoplásicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha